We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+20.92%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.42B
AUM Growth
+$350M
Cap. Flow
+$135M
Cap. Flow %
5.56%
Top 10 Hldgs %
42.31%
Holding
83
New
4
Increased
11
Reduced
18
Closed
3

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$67.3M
2
THRD
Third Harmonic Bio
THRD
+$63.1M
3
RVMD icon
Revolution Medicines
RVMD
+$22M
4
ALLK
Allakos
ALLK
+$21M
5
VERV
Verve Therapeutics
VERV
+$20.7M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$32.9M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$25.1M
3
EQRX
EQRx, Inc. Common Stock
EQRX
+$23.4M
4
MRUS
Merus
MRUS
+$15.2M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.61B
$173M 7.15%
21,751,284
– –
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.76B
$127M 5.25%
2,872,953
+1,596,379
+125% +$67.3M
GHRS icon
3
GH Research
GHRS
$1.96B
$108M 4.45%
9,275,158
– –
KYMR icon
4
Kymera Therapeutics
KYMR
$8.72B
$102M 4.22%
4,692,604
+553,846
+13% +$14.6M
RPTX
5
DELISTED
Repare Therapeutics
RPTX
$101M 4.15%
8,291,988
– –
RLAY icon
6
Relay Therapeutics
RLAY
$4.15B
$97.1M 4.01%
4,339,521
-45,284
-1% -$994K
CGEM icon
7
Cullinan Oncology
CGEM
$1.06B
$96.3M 3.98%
7,509,059
– –
RLMD icon
8
Relmada Therapeutics
RLMD
$549M
$76.9M 3.18%
2,078,220
+419,000
+25% +$11.6M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.87B
$72.3M 2.98%
3,678,947
– –
RCUS icon
10
Arcus Biosciences
RCUS
$3.55B
$71.1M 2.94%
2,717,020
-1,243,928
-31% -$32.9M
MRUS
11
DELISTED
Merus
MRUS
$69M 2.85%
3,444,420
-637,011
-16% -$15.2M
THRD
12
DELISTED
Third Harmonic Bio
THRD
$66.4M 2.74%
+3,501,814
New +$63.1M
XOMA
13
DELISTED
Xoma
XOMA
$64.7M 2.67%
3,611,494
+80,951
+2% +$1.67M
RVMD icon
14
Revolution Medicines
RVMD
$40.4B
$64.2M 2.65%
3,255,588
+1,000,000
+44% +$22M
ACRS icon
15
Aclaris Therapeutics
ACRS
$736M
$62.6M 2.59%
3,976,543
– –
CTIC
16
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$51.3M 2.12%
8,813,021
-116,669
-1% -$727K
IDYA icon
17
IDEAYA Biosciences
IDYA
$3.47B
$49.2M 2.03%
3,294,859
+500,000
+18% +$6.49M
KURA icon
18
Kura Oncology
KURA
$830M
$43.8M 1.81%
3,203,783
– –
PNT
19
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$43.2M 1.79%
5,590,048
+2,222,222
+66% +$18.9M
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.7B
$43.2M 1.78%
1,798,085
-558,849
-24% -$12.5M
CINC
21
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$43.1M 1.78%
1,312,443
-331,950
-20% -$9.38M
LXRX icon
22
Lexicon Pharmaceuticals
LXRX
$1.03B
$38.8M 1.6%
16,149,179
+2,000,000
+14% +$5.54M
VRDN icon
23
Viridian Therapeutics
VRDN
$2.14B
$35.7M 1.48%
1,741,840
-2,172
-0.1% -$39K
ITOS
24
DELISTED
iTeos Therapeutics
ITOS
$34.5M 1.43%
1,810,835
-118,366
-6% -$2.73M
XENE icon
25
Xenon Pharmaceuticals
XENE
$6.12B
$32.5M 1.34%
901,095
-696,871
-44% -$25.1M
1
2 3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2022 Portfolio in Review

As of Q3 2022, BVF Inc held 83 positions worth $2.42B, up 17% from $2.07B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

BVF Inc deployed $135M of net new capital in Q3 2022, opening 4 new positions and adding to 11 existing holdings. Its largest new stake was Third Harmonic Bio: 3,501,814 shares worth $66.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $32.9M trimmed.

  • BVF Inc's largest Q3 2022 buy was Third Harmonic Bio: 3,501,814 shares worth $66.4M.
  • BVF Inc added most to Ionis Pharmaceuticals in Q3 2022, an estimated $67.3M increase.
  • BVF Inc's biggest Q3 2022 reduction was Arcus Biosciences, cutting an estimated $32.9M.
  • BVF Inc fully exited Protagonist Therapeutics in Q3 2022, selling an estimated $8.76M.
  • BVF Inc's ten largest holdings make up 42% of its $2.42B portfolio in Q3 2022.
  • BVF Inc opened 4 new positions and closed 3 in Q3 2022.
  • BVF Inc's portfolio value rose 17% quarter-over-quarter to $2.42B.

Based on BVF Inc's 13F filing for Q3 2022, filed 14 Nov 2022.